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Abstract 
Aims: The functional BDNF single nucleotide polymorphism (SNP) rs6265 has been 
associated with many disorders including schizophrenia and alcohol dependence.  However, 
studies have been inconsistent, reporting both positive and negative associations.  Comorbid 
alcohol dependence has a high prevalence in schizophrenia so we investigated the role of 
rs6265 in alcohol dependence in Australian populations of schizophrenia and alcohol 
dependent patients.  
Methods: Two BDNF SNPs rs6265 and a nearby SNP rs7103411 were genotyped in a total 
of 848 individuals.  These included a schizophrenia group (n = 157) and a second 
schizophrenia replication group (n = 235), an alcohol dependent group (n = 231) that had no 
schizophrenia diagnosis and a group of healthy controls (n = 225).  
Results: Allelic association between rs7103411 and comorbid alcohol dependence was 
identified (P = 0.044) in the primary schizophrenia sample.  In the replication study, we were 
able to detect allelic associations between both BDNF SNPs and comorbid alcohol 
dependence (rs6265, P = 0.006; rs7103411, P = 0.014).  Moreover, we detected association 
between both SNPs and risk-taking behaviour after drinking (rs6265, P = 0.005; rs7103411, 
P = 0.009) and we detected strong association between both SNPs and alcohol dependence in 
males (rs6265, P = 0.009; rs7103411, P = 0.013) while females showed association with 
multiple behavioural measures reflecting repetitive alcohol consumption.  Haplotype analysis 
revealed the rs6265-rs7103411 A/C haplotype is associated with comorbid alcohol 
dependence (P = 0.002).  When these SNPs were tested in the non-schizophrenia alcohol 
dependent group we were unable to detect association. 
Conclusion: We conclude that these BDNF SNPs play a role in development of comorbid 
alcohol dependence in schizophrenia while our data does not indicate that they play a role in 
alcohol dependent patients who do not have schizophrenia. 
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1. Introduction 
 
Schizophrenia is a highly heritable and complex disorder affecting 1% of the global 
population. It is a syndrome consisting of a varying number of psychological phenotypes 
depending on the interaction between the genetic background and environmental exposure of 
those affected.  One of the most common comorbid phenotypes found in schizophrenia is 
alcohol dependence.  Previous studies reported a prevalence of up to 55% alcohol 
dependence in schizophrenia cases (Koskinen et al., 2009). 
 
Many genes with a direct neurobiological role have been studied in relation to schizophrenia.  
Brain-derived neurotrophic factor (encoded by the BDNF gene) regulates proliferation and 
survival of nerve cells in the central and peripheral nervous systems (Hartmann et al., 2001).  
Additionally, BDNF influences the activity of dopaminergic systems (Ghosh et al., 1994; 
Guillin et al., 2001).  Changes in BDNF protein, mRNA or receptor levels in the 
hippocampus and cortical regions of the brain have been reported in schizophrenia patients 
(Durany et al., 2001; Takahashi et al., 2000; Weickert et al., 2003), implying that BDNF 
alteration plays a role in schizophrenia pathogenesis.  Hence BDNF is a suitable candidate 
gene for study in schizophrenia. 
 
A functional BDNF single nucleotide polymorphism (SNP) rs6265 has been studied 
extensively because it is within the coding sequence and results in a Val66Met amino acid 
sequence change.  The Met allele is believed to alter intracellular pro-BDNF (immature 
BDNF) trafficking and packaging, therefore altering regulated secretion of mature BDNF 
(Hariri et al., 2003).  Several studies have reported association between rs6265 and 
schizophrenia (Chao et al., 2008; Zakharyan et al., 2011), positive symptoms in 
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schizophrenia (Zhai et al., 2013), and drug response in schizophrenia (Zai et al., 2012b; 
Zhang et al., 2013). However, several studies failed to detect associations between rs6265 
and schizophrenia (Kanazawa et al., 2007; Li et al., 2013; Suchanek et al., 2013; Watanabe et 
al., 2006) and onset age of schizophrenia (Decoster et al., 2011).  Although the biological role 
of BDNF strongly suggests involvement in schizophrenia, the inconsistent findings between 
rs6265 and schizophrenia raises the question of whether rs6265 is involved in a specific 
endophenotype rather than schizophrenia in general.  The rs6265 BDNF SNP has also shown 
association with a number of other psychiatric phenotypes.  A schizophrenia family study 
found association with rs6265, particularly with cognitive deficits (Rosa et al., 2006) but a 
previous family study failed to find association (Egan et al., 2003).  Other studies found 
association between rs6265 and alcohol abuse and related phenotypes (Benzerouk et al., 
2013; Colzato et al., 2011; Shin et al., 2010; Wojnar et al., 2009).  These studies are also 
consistent with human and animal studies showing that low BDNF levels are found in alcohol 
dependence and BDNF down-regulates alcohol induced dopaminergic elevation (Bosse and 
Mathews, 2011; Matsushita et al., 2004; Wojnar et al., 2009). 
 
One study showed that a haplotype involving the BDNF SNPs rs7103411 and rs4923463 was 
associated with comorbid alcohol dependence in bipolar disorder (Neves et al., 2011).  The 
rs4923463 SNP is in the 3'-flanking region of BDNF and rs7103411 is in intron 7 but the 
functional impact of these SNPs on BDNF is unknown.   
 
A number of studies identified the impact of gender on the effect of BDNF polymorphisms 
on various psychiatric phenotypes (Manning and van den Buuse, 2013; Nishichi et al., 2013; 
Suchanek et al., 2013).  This highlights the importance of gender influence on the function of 
BDNF which could explain the inconsistencies between association studies involving BDNF. 
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The objective of this study was to investigate the role of the BDNF SNPs rs6265 and 
rs7103411 in comorbid alcohol dependence in Australian populations of schizophrenia 
patients and in alcohol dependent patients without schizophrenia.  Additionally, the effects of 
gender on the role of the BDNF SNPs in alcohol dependence in both groups were 
investigated. 
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2. Materials and Methods 
 
2.1 Subjects 
 
Two schizophrenia patient groups, one alcohol dependent group and a healthy control group 
were recruited.  The second schizophrenia group served as a replication group. 
 
2.1.1 Schizophrenia Group 1 
 
Schizophrenia group one included 157 schizophrenia patients of European descent who were 
aged between 18 and 65 years.  Diagnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV) diagnosis of schizophrenia was confirmed by at least two independent 
psychiatrists.  Patients were also screened for alcohol use disorder (AUD) using the Alcohol 
Use Disorder Identification Test (AUDIT). Patients scoring at least 12 in AUDIT are 
considered alcohol dependent. AUDIT scores below 12 are considered not alcohol dependent.  
These patients had never been diagnosed with other psychiatric disorders, including 
schizoaffective disorder, major depressive episode with psychotic features, or bipolar 
disorder.  No patients were treated with antidepressants, anxiolytic agents, or mood-
stabilizing psychotropic medications and all were maintained on a constant dose of 
antipsychotic medication for a minimum of three weeks. 
 
There were 23 females and 134 males in the group diagnosed with schizophrenia with a mean 
age of 36.2 years (s.d. + 12.1 years).  The mean age of patients at first diagnosis (onset of 
psychotic symptoms) was 23.2 years (s.d. + 7.3 years).  They were being treated at a large 
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teaching hospital, an inpatient treatment facility or a community mental health centre.  The 
clinical sample was composed of 65 inpatients and 92 outpatients. 
 
This clinical sample was a group who had lived with schizophrenia for an average of 13 years 
since diagnosis and continued to experience positive and negative symptoms despite 
treatment with antipsychotic medication.  Mean length of illness was 13.39 years (s.d ± 
10.91).  In addition, the schizophrenia group contained a high proportion of individuals with 
a relatively severe history and/or a familial risk for psychosis. 
 
2.1.2 The Replication Schizophrenia Group 
 
The second schizophrenia patient group was obtained from the Australian Schizophrenia 
Research Bank (ASRB: www.schizophreniaresearch.org.au) and included 235 schizophrenia 
patients of European descent with a mean age of 43.9 years (s.d + 10.7 years).  There were 70 
females and 165 males with a confirmed diagnosis of schizophrenia according to DSM-
IV/ICD-10 diagnostic criteria with a first diagnosis mean age of 39.4 years (s.d + 10.7 years).  
All participants underwent a clinical and neuropsychological assessment and provided a 
blood sample at the time of assessment.  The participants were assessed using a clinical 
assessment battery that consists of the Diagnostic Interview for Psychosis (DIP) (Castle et al., 
2006) to collect socio-demographic, family and medical history data, and to screen for or 
confirm diagnosis. 
 
The patients were recruited from several sources across five Australian States and Territories 
(New South Wales, Australian Capital Territory, Queensland, Western Australia and 
Victoria) using media advertisements, inpatient, outpatient and community mental health 
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service providers, non-government organisation, rehabilitation services.  To determine 
European descent, the country of origin for the participant, their parents and all grandparents, 
were recorded.  Europe was defined as continental Europe and the British Isles (including 
Turkey but excluding Middle Eastern Europe).  Australians of Aboriginal/Torres Strait Island 
decent were excluded.   
 
2.1.3 Alcohol Dependent Group 
 
A total of 231 unrelated alcohol dependent subjects of European descent (74 female and 157 
male) were recruited from large public hospitals in Brisbane, Australia. The mean age of the 
group was 40.74 years (s.d. ± 10.3 years). All subjects were assessed against a checklist of 
specific criteria by a clinical psychologist experienced in drug and alcohol dependence and 
met DSM-IV criteria of alcohol dependence disorder. All were inpatients and represented a 
spectrum of severity with a significant proportion (n = 65) of these patients being diagnosed 
with two or more alcohol related medical conditions such as pancreatitis, cirrhosis, hepatitis 
or peripheral neuropathy. Alcohol dependent patients were excluded from the study if they 
had dementia, delirium, psychosis, or any other condition that would affect their ability to 
provide informed consent. A large proportion (81%) of the alcohol dependent cohort was also 
smokers. 
 
2.1.4 Control Group 
 
The control group was also obtained from Australian Schizophrenia Research Bank.  The 
controls consisted of 121 females and 104 males of European descent, with a mean age of 
45.00 years (s.d. ± 13.2 years).  Healthy controls were screened for a family history of, or 
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treatment for, a psychiatric illness at the time of registration.  The controls underwent a 
clinical and neuropsychological assessment and provided a blood sample at the time of 
assessment.  The controls were assessed using a clinical assessment battery that consists of 
the Diagnostic Interview for Psychosis (DIP) (Castle et al., 2006) to collect socio-
demographic, family and medical history data. 
 
2.1.5 Ethics Approval 
 
Ethics approval for the project was obtained from the Human Research Ethics Committee of 
the Queensland University of Technology. 
 
2.2 SNP Genotyping 
 
Samples were genotyped for the BDNF SNPs rs6265 and rs710341 using a homogeneous 
MassEXTEND (hME) Sequenom assay performed by the Australian Genome Research 
Facility.  
 
2.3 Statistical Analysis 
 
Association between SNPs and schizophrenia and/or alcohol dependence were determined 
using χ2 tests by comparing frequencies between schizophrenia patients and the control 
group, or schizophrenia patients with and without alcohol dependence.  Clinical measures 
were analysed in SPSS using ANOVA (analysis of variance).Patients in all groups were  
analysed according to gender and power calculations revealed that a sample size of 244 case 
and 244 non-case alleles is required to achieve 80% power at an odds ratio of 1.8 for both 
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SNPs.  In schizophrenia group one, females had 2 case and 38 non-case alleles and males had 
82 case and 158 non-case alleles; in the schizophrenia replication group, females had 124 
case and 238 non-case alleles and males had 296 case and 202 non-case alleles; in the alcohol 
dependent group, females had 124 case and 238 non-case alleles and males had 82 case and 
158 non-case alleles.  Statistical tests were performed using Compare2 (ver. 2.75) 
(Abramson, 2004) and Statistical Package for the Social Sciences (SPSS) 21.  Hardy-
Weinberg equilibrium was computed using Utility Programs for Analysis of Genetic Linkage 
(Ott, 1988) and haplotypes were analysed using JLIN (Carter et al., 2006).  Correction for 
multiple testing for χ2 tests was conducted using the Benjamini-Hochberg method (Benjamini 
and Hochberg, 1995). 
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3. Results 
 
3.1 Schizophrenia Group One 
 
Genotypes for rs6265 and rs7103411 were determined in 42 schizophrenia cases with 
comorbid alcohol use disorder and 99 schizophrenia cases without comorbid alcohol use 
disorder.  The BDNF SNPs were first tested for association with schizophrenia by comparing 
genotype frequencies between schizophrenia group one and the control group. Schizophrenia 
was not significantly associated with rs6265 (P = 0.857) nor rs7103411 (P = 0.579) at the 
genotype level.  All genotype frequencies were found to be in Hardy-Weinberg equilibrium 
for both the schizophrenia and control populations. 
 
We then tested both SNPs for association with alcohol-related phenotypes within 
schizophrenia. Patients in schizophrenia group one were screened for alcohol use disorders 
using the Alcohol Use Disorders Identification Test (AUDIT).  A cut-off score of 12 was 
used instead of the recommended score, 8 to achieve higher level of specificity, therefore 
reducing false positives (Babor et al., 2001).  Patients scoring at least 12 are considered 
alcohol dependent while scores below 12 are considered not alcohol dependent. We also 
further tested the SNPs against alcohol-related behavioural measures to identify if the SNPs 
were associated with specific alcohol-related behavioural variability.  The alcohol-related 
behaviours were measured using the Drinking Expectancy Questionnaire (DEQ) and 
Drinking Refusal Self Efficacy Questionnaire (DRSEQ), which measure behavioural change 
upon alcohol consumption and ability to refrain from alcohol use (Li and Dingle, 2012; Oei et 
al., 2005) respectively.  Lastly, haplotype analysis was performed to investigate association 
between haplotypes and comorbid alcohol dependence. 
13 
 
 
Genotypes for rs6265 were marginally associated (P = 0.046) with comorbid alcohol 
dependence after trend analysis (Table 1) but rs6265 was not associated at the allele level 
(Table 2).  The rs7103411 SNP was associated at genotype level after trend analysis (P = 
0.014) and at the allele level (P = 0.044), with TT being the low-risk genotype (Table 1).  
ANOVA did not detect any significant differences between the SNP genotypes and DEQ 
scores, DRSEQ scores and drinking quantities over time.  Haplotype analysis revealed strong 
linkage disequilibrium (LD) (D´ = 1) between rs6265 and rs7103411 but no significant 
haplotype association with comorbid alcohol dependence was detected (P = 0.195). 
 
When the schizophrenia patients were grouped according to gender, neither rs6265 nor 
rs7103411 were associated at the allele or genotype level.  However, in the male 
schizophrenia patients, trend analysis revealed association between comorbid alcohol 
dependence and both rs6265 (P = 0.031), and rs7103411 (P = 0.012) genotypes.  At the allele 
level, only rs7103411 was associated with comorbid alcohol dependence (P = 0.036).  
ANOVA did not detect any significant differences between both SNP genotypes and DEQ 
scores, DRSEQ scores and drinking quantities over time in both male and female patients. 
 
3.2 The Replication Schizophrenia Group 
 
Genotypes for rs6265 and rs7103411 were determined for the second set of schizophrenia 
cases and controls.  In total, 72 schizophrenia cases with comorbid alcohol dependence and 
162 schizophrenia cases without comorbid alcohol dependence were genotyped. 
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No association with schizophrenia was detected for either rs6265 (P = 0.731) or rs7103411 
(P = 0.910) at the genotype level. 
 
When comorbid alcohol dependence was examined among the cases associations with both 
rs6265 (P = 0.013) and rs7103411 (P = 0.017) were detected at the genotype level (Table 3).  
Mantel-Haenszel trend test also revealed significant comorbid alcohol dependence 
association for both rs6265 (P = 0.003) and rs7103411 (P = 0.006) genotypes using a partial 
dominance model (Table 3).  The rs6265 odds ratio suggests a trend from the low-risk GG 
genotype, followed by AG and AA being the high-risk genotype (Table 3).  As for 
rs7103411, TT is the lowest risk genotype, followed by CT and CC (Table 3).  In agreement 
with the partial dominance model, allele association also revealed significant association 
between the high-risk alleles (rs6265 A allele and rs7103411 C allele) and comorbid alcohol 
dependence (Table 4).  
 
ANOVA was performed to identify SNP associations with alcohol-related behavioural 
measures.  These measures were scored based on the scale of clinical assessment battery from 
the Diagnostic Interview for Psychosis (DIP) under the ‘alcohol use’ domain.  The measures 
include drinks consumed per session, risk taking behaviour, alcohol craving, inability to stop 
drinking, alcohol tolerance, withdrawal, social problems related to alcohol, attempts to reduce 
alcohol consumption, guilt from alcohol consumption and need for morning alcohol 
consumption.  Risk taking behaviour (use of alcohol in situations increasing risk of injury to 
self and others) was found associated with both rs6265 (P = 0.005, F = 5.577) and rs7103411 
(P = 0.009, F = 4.860) in schizophrenia (Figure 1).  High ‘risk taking behaviour’ scores were 
associated with the rs6265 AA genotype and the rs7103411 CC genotype.  Haplotype 
analysis revealed an overall haplotype association with comorbid alcohol dependence (P = 
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0.008), with the high-risk AC haplotype strongly associated with alcohol dependence (P = 
0.002).  No other alcohol-related behavioural measures were found associated with rs6265 or 
rs7103411.  
 
When analysed by gender, neither rs6265 (P = 0.077) nor rs7103411 (P = 0.059) were 
associated with comorbid alcohol dependence in females but they did show association with 
alcohol-related behavioural measures; “need for morning alcohol consumption” (P = 0.004, F 
= 6.121), “attempts to reduce alcohol consumption” (P = 0.028, F = 3.928), “alcohol 
tolerance” (P = 0.001, F = 7.738), “withdrawal” (P = 0.003, F = 6.862), and “social problems 
related to alcohol” (P = 0.001, F = 7.639) for the AA genotype of rs6265. These measures 
also survived post-hoc Tukey test for AA compared with AG and GG genotypes, except 
“attempts to reduce alcohol consumption” achieved near significance between AA and AG 
genotypes (Tukey’s P = 0.052). Similarly, the CC genotype of rs7103411 was associated 
with the same measures of “need for morning alcohol consumption” (P = 0.012, F = 4.853), 
“attempts to reduce alcohol consumption” (P = 0.028, F = 3.928), “alcohol tolerance” (P = 
0.001, F = 7.738), “withdrawal” (P = 0.003, F = 6.862), and “social problems related to 
alcohol” (P = 0.001, F = 7.639) and survived post-hoc tests except for “attempts to reduce 
alcohol consumption” (Tukey’s P = 0.052) between CC and CT genotypes. 
 
In male schizophrenia patients with comorbid alcohol dependence both rs6265 (P = 0.009) 
and rs7103411 (P = 0.013) genotypes and alleles, rs6265 (P = 0.016) and rs7103411 (P = 
0.028) were associated.  SNPs rs6265 and rs7103411 both survived corrections and there 
were significant differences between AA and AG (Tukey’s P = 0.024), and between CC and 
CT (Tukey’s P = 0.036) genotypes. 
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3.3 Alcohol Dependent Group 
 
Genotypes for rs6265 and rs7103411 were determined for the alcohol dependent group in 210 
cases and 220 controls.  Neither SNP was associated with alcohol dependence at the genotype 
level and only rs6265 alleles showed marginal association (P = 0.046), although this did not 
survive correction for multiple testing. Similarly, haplotypes were not associated (P = 0.208) 
with alcohol dependence and no association was seen after analysing by gender.  
 
  
 
4. Discussion 
 
In this study, BDNF SNPs rs6265 and rs7103411 were not associated with schizophrenia in 
two schizophrenia sample groups.  However, the SNPs were weakly associated with 
comorbid alcohol dependence in our first schizophrenia group and much stronger association 
was found with comorbid alcohol dependence for both rs6265 and rs7103411when a larger 
replication schizophrenia group were tested.  The differences in results between the original 
and the replication schizophrenia groups may be due to the smaller number of cases in the 
original group.   
 
To our knowledge, no studies investigating associations of BDNF SNPs rs6265 and 
rs7103411 with comorbid alcohol dependence in schizophrenia have been published.  
Consistent with several previous studies (Decoster et al., 2011; Kanazawa et al., 2007; Li et 
al., 2013; Suchanek et al., 2013; Watanabe et al., 2006), we report no association between 
rs6265 and schizophrenia.  Previous association studies involving rs6265 and alcohol 
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dependence have had inconsistent findings with some detecting association (Benzerouk et al., 
2013; Colzato et al., 2011; Shin et al., 2010; Wojnar et al., 2009) while others failed to detect 
association (Nedic et al., 2013).  Our study approached significance but we were not able to 
detect association between the two BDNF SNPs and alcohol dependence.  
 
Interestingly, association was found with both rs6265 and rs7103411 in schizophrenia 
patients with comorbid alcohol dependence but there was no association in alcohol dependent 
individuals without schizophrenia.  These results suggest a possible role of both BDNF SNPs 
in the aetiology of comorbid alcohol dependence phenotype in schizophrenia.  Analysis of the 
BDNF SNPs and alcohol-related behaviour in the replication schizophrenia group revealed 
that both rs6265 and rs7103411 are associated with risk of self-injuries and injuries to others, 
which also has been reported in similar studies (Paska et al., 2013; Sarchiapone et al., 2008; 
Zai et al., 2012a).  When schizophrenia patients were analysed by gender, both BDNF SNPs 
were associated with comorbid alcohol dependence in females but not males.  Analysis of 
alcohol-related behaviour measures revealed that both BDNF SNPs were associated with a 
number of alcohol-related behaviour measures based on gender.  In males, they were 
associated with risk taking behaviour, while females showed association with behaviours 
reflecting repetitive alcohol consumption.  Our results are consistent with previous studies 
which reported BDNF variants induced gender-specific effects leading to gender-specific 
phenotypic outcomes (Manning and van den Buuse, 2013; Nishichi et al., 2013; Suchanek et 
al., 2013).  One similar study however, did not find any gender-specific association in alcohol 
dependent subjects between BDNF and alcohol-related phenotypes including depression, 
aggression, suicidal behaviour, delirium and withdrawal (Nedic et al., 2013).  These results 
strongly suggest that BDNF elicits different behavioural effects and plays a different 
aetiological role based on gender.  In line with a mouse study, males with reduced BDNF 
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levels treated with amphetamine elicited reduced prepulse inhibition (a signal involved in the 
pathways for psychosis) but not in females (Manning and van den Buuse, 2013). 
 
A recent meta-analysis revealed inconsistent findings in eight association studies of rs6265 
and alcohol abuse (Haerian, 2013).  However, the meta-analysis found that these 
inconsistencies were largely due to differences between European populations that generally 
were not associated and Asian populations (particularly Japanese and Taiwanese) that all 
showed association.  It may be that the function of BDNF is modified by underlying genetic 
differences in these two population groups.  Taking our study into consideration, it may be 
that the rs6265 Met allele has a role in alcohol dependence in both European and Asian 
schizophrenia populations and in Asians without schizophrenia but not in Europeans without 
schizophrenia due to underlying genetic differences between populations.  This is also 
consistent with several studies reporting different psychiatric phenotype outcomes as well as 
different allele frequencies for BDNF variants due to population differences (Gratacos et al., 
2007; Petryshen et al., 2010; Pivac et al., 2009). 
 
One of the clinical features closely linked to alcohol dependence and alcohol use disorders is 
depression.  Depression and poor mental health have been long identified to be closely linked 
and are risk factors to alcohol abuse (Briere et al., 2013; Davidson, 1995; Weitzman, 2004).  
BDNF variants have also been studied for association with depressive disorders and evidence 
of association has been found (Lavebratt et al., 2010; Lee et al., 2013; Pei et al., 2012; 
Ribeiro et al., 2007; Suchanek et al., 2011).  Unlike positive reinforcement for alcohol 
consumption (reward driven drinking), depression may serve as a negative reinforcing factor 
(drinking behaviour caused by the need to alleviate the effects of depression) for alcohol 
abuse (Gilpin and Koob, 2008).  It is therefore possible that these BDNF SNPs play a role in 
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depression which leads to alcohol dependence although depression was not examined in the 
present study. 
 
Two studies have demonstrated that mice with low BDNF levels consumed more alcohol 
compared to mice with high BDNF levels (Bahi and Dreyer, 2013; Jeanblanc et al., 2009).  
BDNF mainly modulates the activity of the serotonin/dopamine pathway by binding with 
receptor tyrosine kinase B (TrkB) which induces expression of the dopamine D3 receptor 
(Jeanblanc et al., 2006).  Blockade of the dopamine D3 receptor has been shown to decrease 
alcohol consumption in rats (Thanos et al., 2005).  These data support a key role for BDNF as 
a genetic risk factor in the development of alcohol dependence. 
 
While many studies have proposed that BDNF variants are associated with various 
psychiatric disorders that are generally comprised of multiple and complex clinical 
symptoms, it may be more profitable to target specific clinical symptoms rather than the 
primary diagnosis.  To further validate our positive association findings on comorbid alcohol 
dependence, replication studies with larger sample sizes screened for a range of alcohol-
related parameters within schizophrenia, along with a non-schizophrenia alcohol dependent 
sample screened for alcohol-related parameters is required to elucidate the role of rs6265 and 
rs7103411. 
 
5. Conclusion 
 
We conclude that the BDNF gene, particularly the SNPs, rs6265 and rs7103411, play an 
important role in the development of comorbid alcohol dependence in schizophrenia patients 
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but it is not clear that they have any role in the development of alcohol dependence in 
individuals without schizophrenia. 
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Tables and Figures 
 
Table 1: Schizophrenia group one BDNF genotype association with comorbid alcohol 
dependence in schizophrenia 
 
SNP Genotype frequencies χ2 P  
rs6265 AA AG GG*   
Alcohol dependent+ 2 18 22  0.152a 
Alcohol dependent- 1 33 64 2.853 b 0.046b 
Odds ratioc 5.818 1.587 1.000   
Odds ratio P 0.288 0.460      
rs7103411 CC CT TT*   
Alcohol dependent+ 2 19 20  0.071 a 
Alcohol dependent- 1 32 66 4.793 b 0.014b 
Odds ratio 6.600 1.959 1.000   
Odds ratio P 0.237 0.164  
 
 
 
Alcohol dependent+, schizophrenia patients with alcohol dependence; alcohol dependent-, 
schizophrenia patients without alcohol dependence 
* Low-risk genotype, due to higher proportion in schizophrenia patients without alcohol dependence 
a Fisher’s exact test 
b Mantel-Haenszel test for trend in a given direction 
c Odds ratio calculated with respect to the low-risk genotype 
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Table 2: Schizophrenia group one BDNF allele association with comorbid alcohol 
dependence in schizophrenia 
 
SNP Allele frequencies χ
2 P 
rs6265 A G*   
Alcohol dependent+ 22 62 
2.435 0.119a 
Alcohol dependent- 35 161 
Odds ratiob 1.630 1.000     
rs7103411 C T*   
Alcohol dependent+ 23 59 
4.051 0.044 
Alcohol dependent- 34 164 
Odds ratio 1.880 1.000   
 
Alcohol dependent+: schizophrenia patients with alcohol dependence; Alcohol dependent-: 
schizophrenia patients without alcohol dependence. 
* Low-risk allele 
a Likelihood ratio chi-square P value 
b Odds ratio calculated with respect to the low-risk allele 
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Table 3: Schizophrenia replication group BDNF genotype association with comorbid alcohol 
dependence in schizophrenia 
 
SNP Genotype frequencies χ2 P  
rs6265 AA AG GG*   
Alcohol dependent+ 7 25 40 8.716 a 0.013a 
Alcohol dependent- 3 46 113 7.48 b 0.003b 
Odds ratioc 6.592 1.535 1   
Odds ratio P 0.011 0.336       
rs7103411 CC CT TT*   
Alcohol dependent+ 7 27 38 8.153 a 0.017 a 
Alcohol dependent- 3 53 106 6.332 b 0.006 b 
Odds ratioc 6.509 1.421 1   
Odds ratio P 0.011 0.495    
 
Alcohol dependent+, schizophrenia patients with comorbid alcohol dependence; alcohol dependent-, 
schizophrenia patients without comorbid alcohol dependence 
* Low-risk genotype, due to higher proportion in schizophrenia patients without alcohol dependence 
a Likelihood ratio chi-square  
b Mantel-Haenszel test for trend in a given direction 
c Odds ratio calculated with respect to the low-risk genotype 
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Table 4: Schizophrenia replication group BDNF allele association with comorbid alcohol 
dependence in schizophrenia 
 
SNP Allele frequencies χ
2 P 
rs6265 A G*   
Alcohol dependent+ 39 105 
7.424 0.006a 
Alcohol dependent- 52 272 
Odds ratiob 1.940 1.000     
rs7103411 C T*   
Alcohol dependent+ 41 103 
6.029 0.014 
Alcohol dependent- 59 265 
Odds ratio 1.790 1.000   
 
Alcohol dependent+: schizophrenia patients with comorbid alcohol dependence; Alcohol 
dependent-: schizophrenia patients without comorbid alcohol dependence 
* Low-risk allele 
a Likelihood ratio chi-square P-value 
b Odds ratio calculated with respect to the low-risk allele 
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Figure 1: Association of risk taking behaviour with BDNF. 
Risk taking behaviour score (mean and ±SE) with BDNF genotypes for, rs6265 and 
rs7103411.  ANOVA post-hoc multiple comparison was performed for rs6265 and rs7103411 
using AA and CC genotypes respectively as comparison.  
Footnotes 
*Tukey P < 0.05 
**Tukey P < 0.01 
 
 
